The company says its AI and synthetic biology platform can produce compounds not possible with traditional synthesis ...

Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...

Leading synthetic biologists have shared hard-won lessons from their decade-long quest to build the world's first synthetic ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 ...

A major pharmaceutical company is making an announcement on Tuesday regarding growth of biopharma innovation in the Rocket ...

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply ...

PREVIOUS COVERAGE - Pharmaceutical giant Eli Lilly and Company announced Tuesday a massive $6 billion investment to build a ...

The pharmaceutical giant's investment in Huntsville will be a huge boost to the local economy, underscoring its rising ...

Norfolk Southern will serve a new $6 billion Eli Lilly and Co. manufacturing campus that the pharmaceutical company will ...

The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.

Eli Lilly plans API plant in Alabama to produce small molecule and peptide medicines, creating 450 jobs and enhancing U.S. pharmaceutical supply chains.